No title
BackgroundPediatric heart-lung transplantation (pHLTx) remains the only treatment option for children with significant and fixed elevation of pulmonary vascular resistance (PVR) in the setting of uncorrectable end-stage heart disease. We aimed to determine the characteristics, waiting list course and long-term outcomes for children listed for pHLTx within the Scandiatransplant region.MethodsThis w
